



NDA 19-643/S-067

Merck & Co., Inc.  
Attention: Michael C. Elia, Ph.D.  
Director, Regulatory Affairs  
Sumneytown Pike, P.O. Box 4, BLA-20  
West Point, PA 19486

Dear Dr. Elia:

Please refer to your supplemental new drug application dated April 16, 2001, received April 17, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Mevacor (lovastatin) tablets.

We acknowledge receipt of your submissions dated May 4, June 28, July 2 and 18, October 15, and December 18, 2001, and January 23 and February 12, 2002.

This supplemental new drug application provides for the addition of an indication for the treatment of heterozygous familial hypercholesterolemia in a new population of adolescent boys and girls at least one year postmenarchal, ages 10 to 17 years, with a recommended dosing range of 10 to 40 mg once daily of Mevacor (lovastatin) tablets.

The package insert incorporates changes to the following sections regarding the new pediatric use: **CLINICAL PHARMACOLOGY**- "*Clinical Studies*", **INDICATIONS AND USAGE**, **PRECAUTIONS**- "*Pediatric Use*", **ADVERSE REACTIONS**, and **DOSAGE AND ADMINISTRATION**.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert submitted on February 12, 2002).

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30

days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 19-643/S-067." Approval of this submission by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Margaret Simoneau, R.Ph., Regulatory Project Manager, at (301) 827-6411.

Sincerely,

*{See appended electronic signature page}*

David G. Orloff, M.D.  
Director  
Division of Metabolic and Endocrine Drug Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

Enclosure

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
David Orloff

2/14/02 08:10:11 PM